A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer

Update Il y a 4 ans
Reference: EUCTR2005-001893-28

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare event free survival (EFS) between postmenopausal women treated with exemestane or anastrozole as adjuvant therapy.


Inclusion criteria

  • Post-menopausal women, histologically or cytologically confirmed, receptor-positive, adequately excised, primary breast cancer